Breaking News: NewAmsterdam Pharma Successfully Closes Oversized $479 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Ordinary Shares and Pre-Funded Warrants!
NAARDEN, The Netherlands and MIAMI, Dec. 13, 2024 (GLOBE NEWSWIRE) —
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the closing of the previously announced underwritten public offering of (i) 14,667,347 of the Company’s ordinary shares, nominal value €0.12 per share (the “Ordinary Shares”), at a public offering price of $24.50 per share, which includes the exercise in full of the underwriters’ option to purchase an additional 2,550,000 Ordinary Shares, and (ii) to certain investors that so choose in lieu of Ordinary Shares, pre-funded warrants to purchase 4,882,653 Ordinary Shares at a public offering price of $24.4999 per pre-funded warrant, which represents the per share public offering price for the Ordinary Shares less the $0.0001 per share exercise price for each such pre-funded warrant (such offering, the “Offering”). All of the securities sold in the Offering were sold by the Company.
Effect on Me:
As an individual, the successful closing of NewAmsterdam Pharma’s public offering may not have an immediate impact on you. However, if you are someone with elevated LDL-C and are at risk of cardiovascular disease, the development of new oral, non-statin medicines by the Company could provide you with additional treatment options in the future.
Effect on the World:
The successful closing of this public offering by NewAmsterdam Pharma signifies a significant investment in the development of new treatments for cardiovascular disease. This has the potential to benefit patients worldwide who struggle with elevated cholesterol levels and cardiovascular health. The Company’s innovative approach to developing non-statin medicines could pave the way for improved therapies globally.
Conclusion:
In conclusion, the successful closure of NewAmsterdam Pharma’s oversized public offering is a promising development in the field of cardiovascular disease treatment. With a focus on patients who do not respond well to existing therapies, the Company’s efforts could lead to groundbreaking advancements in the management of LDL-C levels and overall cardiovascular health. The impact of this achievement is not only significant for individuals at risk of CVD but also holds promise for the broader global community in need of more effective treatment options. Keep an eye out for further updates from NewAmsterdam Pharma as they continue their important work in bringing innovative medicines to those in need.
